Research ArticleArticle
Open Access
Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial
Gurjit S. Kaeley, Amy M. Evangelisto, Midori J. Nishio, Sandra L. Goss, Shufang Liu, Jasmina Kalabic and Hartmut Kupper
The Journal of Rheumatology June 2016, jrheum.151009; DOI: https://doi.org/10.3899/jrheum.151009
Gurjit S. Kaeley
From the University of Florida College of Medicine, Jacksonville, Florida; Arthritis, Rheumatic and Back Disease Associates, Voorhees, New Jersey; Diablo Clinical Research, Walnut Creek, California; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. GSK is a consultant for AbbVie Inc. AME has received research grants and served as a speaker for AbbVie Inc. SLG is an employee of AbbVie and owns stock. SL is a former employee of AbbVie and owns stock options. JK and HK are full-time employees of AbbVie and own stock or stock options. G.S. Kaeley, MBBS, MRCP, University of Florida College of Medicine; A.M. Evangelisto, MD, Arthritis, Rheumatic and Back Disease Associates; M.J. Nishio, MD, Diablo Clinical Research; S.L. Goss, PhD, AbbVie Inc.; S. Liu, PhD, AbbVie Inc.; J. Kalabic, MD, AbbVie Inc.; H. Kupper, MD, AbbVie Deutschland GmbH and Co. KG. Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653-1 West 8th St., LRC 2nd Floor L-14, Jacksonville, Florida 32209-6561, USA. E-mail: Gurjit.Kaeley@jax.ufl.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication April 19, 2016.
Amy M. Evangelisto
From the University of Florida College of Medicine, Jacksonville, Florida; Arthritis, Rheumatic and Back Disease Associates, Voorhees, New Jersey; Diablo Clinical Research, Walnut Creek, California; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. GSK is a consultant for AbbVie Inc. AME has received research grants and served as a speaker for AbbVie Inc. SLG is an employee of AbbVie and owns stock. SL is a former employee of AbbVie and owns stock options. JK and HK are full-time employees of AbbVie and own stock or stock options. G.S. Kaeley, MBBS, MRCP, University of Florida College of Medicine; A.M. Evangelisto, MD, Arthritis, Rheumatic and Back Disease Associates; M.J. Nishio, MD, Diablo Clinical Research; S.L. Goss, PhD, AbbVie Inc.; S. Liu, PhD, AbbVie Inc.; J. Kalabic, MD, AbbVie Inc.; H. Kupper, MD, AbbVie Deutschland GmbH and Co. KG. Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653-1 West 8th St., LRC 2nd Floor L-14, Jacksonville, Florida 32209-6561, USA. E-mail: Gurjit.Kaeley@jax.ufl.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication April 19, 2016.
Midori J. Nishio
From the University of Florida College of Medicine, Jacksonville, Florida; Arthritis, Rheumatic and Back Disease Associates, Voorhees, New Jersey; Diablo Clinical Research, Walnut Creek, California; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. GSK is a consultant for AbbVie Inc. AME has received research grants and served as a speaker for AbbVie Inc. SLG is an employee of AbbVie and owns stock. SL is a former employee of AbbVie and owns stock options. JK and HK are full-time employees of AbbVie and own stock or stock options. G.S. Kaeley, MBBS, MRCP, University of Florida College of Medicine; A.M. Evangelisto, MD, Arthritis, Rheumatic and Back Disease Associates; M.J. Nishio, MD, Diablo Clinical Research; S.L. Goss, PhD, AbbVie Inc.; S. Liu, PhD, AbbVie Inc.; J. Kalabic, MD, AbbVie Inc.; H. Kupper, MD, AbbVie Deutschland GmbH and Co. KG. Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653-1 West 8th St., LRC 2nd Floor L-14, Jacksonville, Florida 32209-6561, USA. E-mail: Gurjit.Kaeley@jax.ufl.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication April 19, 2016.
Sandra L. Goss
From the University of Florida College of Medicine, Jacksonville, Florida; Arthritis, Rheumatic and Back Disease Associates, Voorhees, New Jersey; Diablo Clinical Research, Walnut Creek, California; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. GSK is a consultant for AbbVie Inc. AME has received research grants and served as a speaker for AbbVie Inc. SLG is an employee of AbbVie and owns stock. SL is a former employee of AbbVie and owns stock options. JK and HK are full-time employees of AbbVie and own stock or stock options. G.S. Kaeley, MBBS, MRCP, University of Florida College of Medicine; A.M. Evangelisto, MD, Arthritis, Rheumatic and Back Disease Associates; M.J. Nishio, MD, Diablo Clinical Research; S.L. Goss, PhD, AbbVie Inc.; S. Liu, PhD, AbbVie Inc.; J. Kalabic, MD, AbbVie Inc.; H. Kupper, MD, AbbVie Deutschland GmbH and Co. KG. Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653-1 West 8th St., LRC 2nd Floor L-14, Jacksonville, Florida 32209-6561, USA. E-mail: Gurjit.Kaeley@jax.ufl.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication April 19, 2016.
Shufang Liu
From the University of Florida College of Medicine, Jacksonville, Florida; Arthritis, Rheumatic and Back Disease Associates, Voorhees, New Jersey; Diablo Clinical Research, Walnut Creek, California; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. GSK is a consultant for AbbVie Inc. AME has received research grants and served as a speaker for AbbVie Inc. SLG is an employee of AbbVie and owns stock. SL is a former employee of AbbVie and owns stock options. JK and HK are full-time employees of AbbVie and own stock or stock options. G.S. Kaeley, MBBS, MRCP, University of Florida College of Medicine; A.M. Evangelisto, MD, Arthritis, Rheumatic and Back Disease Associates; M.J. Nishio, MD, Diablo Clinical Research; S.L. Goss, PhD, AbbVie Inc.; S. Liu, PhD, AbbVie Inc.; J. Kalabic, MD, AbbVie Inc.; H. Kupper, MD, AbbVie Deutschland GmbH and Co. KG. Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653-1 West 8th St., LRC 2nd Floor L-14, Jacksonville, Florida 32209-6561, USA. E-mail: Gurjit.Kaeley@jax.ufl.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication April 19, 2016.
Jasmina Kalabic
From the University of Florida College of Medicine, Jacksonville, Florida; Arthritis, Rheumatic and Back Disease Associates, Voorhees, New Jersey; Diablo Clinical Research, Walnut Creek, California; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. GSK is a consultant for AbbVie Inc. AME has received research grants and served as a speaker for AbbVie Inc. SLG is an employee of AbbVie and owns stock. SL is a former employee of AbbVie and owns stock options. JK and HK are full-time employees of AbbVie and own stock or stock options. G.S. Kaeley, MBBS, MRCP, University of Florida College of Medicine; A.M. Evangelisto, MD, Arthritis, Rheumatic and Back Disease Associates; M.J. Nishio, MD, Diablo Clinical Research; S.L. Goss, PhD, AbbVie Inc.; S. Liu, PhD, AbbVie Inc.; J. Kalabic, MD, AbbVie Inc.; H. Kupper, MD, AbbVie Deutschland GmbH and Co. KG. Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653-1 West 8th St., LRC 2nd Floor L-14, Jacksonville, Florida 32209-6561, USA. E-mail: Gurjit.Kaeley@jax.ufl.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication April 19, 2016.
Hartmut Kupper
From the University of Florida College of Medicine, Jacksonville, Florida; Arthritis, Rheumatic and Back Disease Associates, Voorhees, New Jersey; Diablo Clinical Research, Walnut Creek, California; AbbVie Inc., North Chicago, Illinois, USA; AbbVie Deutschland GmbH and Co. KG., Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. GSK is a consultant for AbbVie Inc. AME has received research grants and served as a speaker for AbbVie Inc. SLG is an employee of AbbVie and owns stock. SL is a former employee of AbbVie and owns stock options. JK and HK are full-time employees of AbbVie and own stock or stock options. G.S. Kaeley, MBBS, MRCP, University of Florida College of Medicine; A.M. Evangelisto, MD, Arthritis, Rheumatic and Back Disease Associates; M.J. Nishio, MD, Diablo Clinical Research; S.L. Goss, PhD, AbbVie Inc.; S. Liu, PhD, AbbVie Inc.; J. Kalabic, MD, AbbVie Inc.; H. Kupper, MD, AbbVie Deutschland GmbH and Co. KG. Address correspondence to Dr. G.S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, 653-1 West 8th St., LRC 2nd Floor L-14, Jacksonville, Florida 32209-6561, USA. E-mail: Gurjit.Kaeley@jax.ufl.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication April 19, 2016.
Article Figures & Data
Additional Files
Data Supplement
Data Supplement
Files in this Data Supplement:
- Data Supplement - Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial
Gurjit S. Kaeley, Amy M. Evangelisto, Midori J. Nishio, Sandra L. Goss, Shufang Liu, Jasmina Kalabic, Hartmut Kupper
The Journal of Rheumatology Jun 2016, jrheum.151009; DOI: 10.3899/jrheum.151009
Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial
Gurjit S. Kaeley, Amy M. Evangelisto, Midori J. Nishio, Sandra L. Goss, Shufang Liu, Jasmina Kalabic, Hartmut Kupper
The Journal of Rheumatology Jun 2016, jrheum.151009; DOI: 10.3899/jrheum.151009